Evaluating the efficacy and complication of Matridex in soft tissue augmentation

Matridex is a filler containing hyaluronic acid polymers, hypermelosis and dextran that affects on the fibroblasts and macrophayes to induce soft tissue augmentation. The aim of this study was to evaluate the longevity and complications of Matridex for soft tissue augmentation in facial atrophic lesions. Fifty patients with scars and wrinkles on the skin face were included in this study. The depth of the lesions was divided to 5 grades. Patients were re-evaluated 2 weeks, 3 and 6 months and 1 year after injection. Data were analyzed by SPSS software. After 6 months, 78% had less absorption of the filler and after one year, 16% had still the filler in the treated area. There was significant difference between depth of the lesions before injection and 6 months and 1 year after treatment. After 6 months follow up 81.8 % had completely absorption in NLF area and 18.2% in glabella area. There was no significant difference between the volume of injection and absorption after 6 months, while there found significant difference after one year. There were no long- term complications and 16% showed short- term complications. Longevity of Matridex is between 6 months and one year in most patients. Some patients may have more than one year longevity. No serious complications were noted by using this filler.